CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc., (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke, M.D., FCP, as Executive Vice President and Chief Medical Officer. Dr. von Moltke joins Seres with an extensive career that includes senior leadership positions at Alkermes, Sanofi Genzyme and Millennium Pharmaceuticals/Takeda Oncology.
“We are thrilled to welcome Dr. Lisa von Moltke as a key addition to our team. Lisa is joining Seres during an especially important period ahead of our anticipated SER-109 ECOSPOR III Phase 3 clinical readout in recurrent C. difficile infection,” said Eric Shaff, President and Chief Executive Officer of Seres. “Seres will benefit from Lisa’s extensive experience directing successful development programs, leading clinical teams, and interacting with regulatory agencies across multiple areas of medicine.”
“I am excited to join Seres during such a pivotal time with the Company advancing promising development-stage therapeutic candidates for C. difficile infection, ulcerative colitis and cancer,” said Dr. von Moltke. “I look forward to working with the team to bring Seres’ innovative microbiome therapeutic approach, a new modality of medicine, forward to patients with serious diseases.”
Dr. von Moltke most recently served as Senior Vice President and Head of Clinical Development at Alkermes. Prior to that, she held positions as Vice President of Clinical and Exploratory Pharmacology at Sanofi Genzyme and Senior Director of Translational Medicine at Millennium Pharmaceuticals/Takeda Oncology. She has served as President of the American College of Clinical Pharmacology and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned her B.A. degree at Wellesley College and her M.D. from Michigan State University College of Human Medicine. She trained in internal medicine at New England Medical Center Hospital and started her career as a clinical pharmacology fellow at Tufts University School of Medicine and New England Medical Center Hospital.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma and SER-301 for ulcerative colitis. For more information, please visit www.serestherapeutics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing and results of each of Seres’ clinical studies, the promise and potential success of microbiome therapeutics, and other statements that are not historical facts.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: We have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development; our ability to manufacture our product candidates, and develop and commercialize our product candidates, if approved; our ability to retain key personnel and to manage our growth; and that our management and principal stockholders have the ability to control or significantly influence our business. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 2, 2020, our Current Report on Form 8-K filed with the SEC on March 18, 2020, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.